These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22439754)

  • 1. New sustained release of zidovudine matrix tablets - cytotoxicity toward Caco-2 cells.
    Santos JV; Pina ME; Marques MP; de Carvalho LA
    Drug Dev Ind Pharm; 2013 Aug; 39(8):1154-66. PubMed ID: 22439754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets.
    Dave VS; Fahmy RM; Bensley D; Hoag SW
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1240-53. PubMed ID: 22257339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
    Baviskar D; Sharma R; Jain D
    Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and in vitro evaluation of zidovudine oral controlled release tablets prepared using hydroxypropyl methylcellulose.
    Ravi PR; Ganga S; Saha RN
    Chem Pharm Bull (Tokyo); 2008 Apr; 56(4):518-24. PubMed ID: 18379101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Carbopol 71G-NF on the release of dextromethorphan hydrobromide from extended-release matrix tablets.
    Fayed MH; Mahrous GM; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(5):971-81. PubMed ID: 21639691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and in vitro, in vivo evaluation of extended- release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers.
    Kuksal A; Tiwary AK; Jain NK; Jain S
    AAPS PharmSciTech; 2006 Jan; 7(1):E1. PubMed ID: 16584139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation development and evaluation of Diltiazem HCl sustained release matrix tablets using HPMC K4M and K100M.
    Qazi F; Shoaib MH; Yousuf RI; Qazi TM; Mehmood ZA; Hasan SM
    Pak J Pharm Sci; 2013 Jul; 26(4):653-63. PubMed ID: 23811439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets.
    Zugasti ME; Zornoza A; Goñi Mdel M; Isasi JR; Vélaz I; Martín C; Sánchez M; Martínez-Ohárriz MC
    Drug Dev Ind Pharm; 2009 Oct; 35(10):1264-70. PubMed ID: 19555243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and in vitro dissolution profile of zidovudine loaded microspheres made of Eudragit RS 100, RL 100 and their combinations.
    Nath B; Nath LK; Kumar P
    Acta Pol Pharm; 2011; 68(3):409-15. PubMed ID: 21648196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citric acid as a solid-state plasticizer for Eudragit RS PO.
    Schilling SU; Shah NH; Malick AW; Infeld MH; McGinity JW
    J Pharm Pharmacol; 2007 Nov; 59(11):1493-500. PubMed ID: 17976259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Soluble Drugs Directly Granulated by Water Dispersions of Insoluble Eudragit® Polymers as a Part of Hypromellose K100M Matrix Systems.
    Mašková E; Naiserová M; Kubová K; Mašek J; Pavloková S; Urbanová M; Brus J; Vysloužil J; Vetchý D
    Biomed Res Int; 2019; 2019():8043415. PubMed ID: 30949510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of dissolution hydrodynamic conditions versus drug release from hypromellose matrices: the influence of agitation sequence.
    Asare-Addo K; Levina M; Rajabi-Siahboomi AR; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Dec; 81(2):452-60. PubMed ID: 20729043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of mixture experimental design in the formulation and optimization of matrix tablets containing carbomer and hydroxy-propylmethylcellulose.
    Petrovic A; Cvetkovic N; Ibric S; Trajkovic S; Djuric Z; Popadic D; Popovic R
    Arch Pharm Res; 2009 Dec; 32(12):1767-74. PubMed ID: 20162406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
    Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
    Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets.
    Vueba ML; Batista de Carvalho LA; Veiga F; Sousa JJ; Pina ME
    Eur J Pharm Biopharm; 2004 Jul; 58(1):51-9. PubMed ID: 15207537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of thermal treatment and type of insoluble poly(meth)acrylates on dissolution behavior of very soluble drug from hypromellose matrix tablets evaluated by multivariate data analysis.
    Kubova K; Peček D; Hasserová K; Doležel P; Pavelková M; Vyslouzil J; Muselík J; Vetchy D
    Pharm Dev Technol; 2017 Mar; 22(2):206-217. PubMed ID: 28058866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous probing of swelling, erosion and dissolution by NMR-microimaging--effect of solubility of additives on HPMC matrix tablets.
    Tajarobi F; Abrahmsén-Alami S; Carlsson AS; Larsson A
    Eur J Pharm Sci; 2009 May; 37(2):89-97. PubMed ID: 19429415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled release matrix tablets of zidovudine: effect of formulation variables on the in vitro drug release kinetics.
    Ravi PR; Kotreka UK; Saha RN
    AAPS PharmSciTech; 2008; 9(1):302-13. PubMed ID: 18446496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of ibuprofen pellets based on Eudragit RS PO and RL PO or their combination.
    Abbaspour MR; Sadeghi F; Garekani HA
    Int J Pharm; 2005 Oct; 303(1-2):88-94. PubMed ID: 16153792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation optimization of solid dispersion of mosapride hydrochloride.
    Kim HJ; Lee SH; Lim EA; Kim JS
    Arch Pharm Res; 2011 Sep; 34(9):1467-75. PubMed ID: 21975808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.